What is it about?
Expression of CD19 on B cell non-Hodgkin lymphoma has identified it as a potential target for immune-based therapies. Various types of CD19 targeted treatments are reviewed and discussed
Why is it important?
Targeted treatments for non-Hodgkin lymphoma often reduce the off-target side effects of conventional chemotherapy, but may cause other unexpected side-effects. These are discussed in this review.
Read the Original
This page is a summary of: CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas, Expert Opinion on Investigational Drugs, July 2018, Taylor & Francis, DOI: 10.1080/13543784.2018.1492549.
You can read the full text:
The following have contributed to this page